News

Long-Term Health-Related Quality of Life With Adjuvant Pembrolizumab in Stage III Melanoma

Survival Outcomes in BRAF-Mutant Melanoma: BRAF/MEK vs PD-1 Inhibitors

BRAF-Mutated Metastatic Melanoma: Predicting Therapeutic Response With ctDNA

Early Results of Combination Regimens With Pembrolizumab in Melanoma

4-Year Follow-up on Lenvatinib Plus Pembrolizumab in Advanced Melanoma

Can FDG-PET Predict Survival and Response to Neoadjuvant Immunotherapy in Melanoma?

Role of Cancer Cell Plasticity in Response to Immunotherapy in Cutaneous Squamous Cell Carcinoma

Nivolumab Plus Relatlimab in Melanoma: 3-Year Survival Outcomes From RELATIVITY-047

MEK Inhibitor in NRAS-Mutated Melanoma: Phase II Trial Update

Lifetime Prevalence of Skin Cancer and Sexual Orientation: Differences by Race and Ethnicity?

Novel Immunotherapy Combination After Anti–PD-1 Therapy Fails in Advanced Melanoma

Stage pT1bN0 Cutaneous Melanoma: Prognostic Factors and Risk Groups

Nivolumab Delivered Through Continuous Intrathecal Infusion for Advanced Melanoma

Long-Term Results With Adjuvant Dabrafenib Plus Trametinib in BRAF-Mutated Melanoma

Tocilizumab Combined With Nivolumab and Ipilimumab in Advanced Melanoma

Exploring Treatment Options for Advanced-Stage Melanoma During Pregnancy

KEYNOTE-629: Long-Term Results With Pembrolizumab in Squamous Cell Skin Cancer

IL-2–Sparing Tumor-Infiltrating Lymphocyte Cell Therapy for Melanoma

Can Radiation Therapy Improve Disease-Specific Survival in Merkel Cell Carcinoma?

When Surgery’s Not an Option: Topical Imiquimod vs Radiotherapy for Lentigo Maligna

CXCR1/2 Inhibitor Plus Pembrolizumab in Metastatic Melanoma: Early-Phase Trial Results

Neoadjuvant Immunotherapy for Squamous Cell Skin Cancer

Lifileucel Plus Pembrolizumab Active in Melanoma Setting in Phase II Trial

Clinician Guidance on Resources for Patients Provided by AIM at Skin Cancer

Novel Monoclonal Antibody and Chemotherapy Under Study in Nonmelanoma Skin Cancer

Vaccine Plus Immunotherapies Under Investigation in Advanced Melanoma

mRNA Vaccine Under Study in Merkel Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma: Predicting Response to Immune Checkpoint Inhibitor Therapy

$600K Grant Awarded to Wistar Researcher to Study Impact of Microbial Genes on Immunotherapy Response in Melanoma

Neoadjuvant Use of Pembrolizumab in Locally Advanced Squamous Cell Skin Cancer

ASCO 2024: Impact of Discontinuing Immunotherapy After Response in Merkel Cell Carcinoma

ASCO 2024: Phase I Findings on Novel Bispecific Protein for Cutaneous Melanoma

ASCO 2024: Triplet Regimen Under Study in High-Risk, Resectable Melanoma

ASCO 2024: Learning About the Impact of Socioeconomic Factors on Superficial Basal Cell Carcinoma

ASCO 2024: KEYNOTE-942 Evaluates mRNA-4157 Plus Pembrolizumab in Resected Melanoma

ASCO 2024: Quality of Life With Neoadjuvant Immunotherapy for Stage III Melanoma

ASCO 2024: Use of Tilsotolimod Plus Ipilimumab vs Ipilimumab Alone in Advanced Melanoma

ASCO 2024: Immunotherapy for Ulcer-Related Squamous Cell Skin Cancer

ASCO 2024: BRAF and MEK Inhibitors Plus Immunotherapy for BRAF V600E/K–Mutated Melanoma

ASCO 2024: Intratumoral Daromun Under Study in Resectable Metastatic Melanoma

ASCO 2024: Risk-Adapted Surgical De-escalation for Resectable Squamous Cell Carcinoma

ASCO 2024: Staging and Treating High-Risk Cutaneous Melanoma During Pregnancy

ASCO 2024: Triplet Immunotherapy Regimen Focus of Study in Advanced Melanoma

ASCO 2024: Phase III Trial Evaluates Neoadjuvant Immunotherapy for Stage III Melanoma

Primary and Metastatic Melanomas: Melanocortin-1 Receptor as Potential Therapeutic Target

HPV ctDNA: Potential Biomarker in Monitoring Response to Treatment in Skin Cancer

Anti–PD-1 Response and Noncoding RNAs in Squamous Cell Skin Cancer

Restoring Drug Sensitivity to BRAF and MEK Inhibition in Double-Resistant Melanoma Cells

Merkel Cell Carcinoma: Potentially Modifiable Risk Factors

Use of High-Frequency Ultrasound in Preoperative Assessment of Melanoma

Potential Alternative to SLNB in Melanoma: Integrated 31-Gene-Expression Profile Test

Italian Oncologists Surveyed on Radiotherapy for Non-Melanoma Skin Cancer

Gene-Expression Profiles and Response to Pembrolizumab in Advanced Squamous Cell Skin Cancer

Impact of Comorbidities on Melanoma Risk and Survival

Can Silibinin Consumption Protect Against UVB-Induced Basal Cell Carcinoma?

Evaluating the Risk of Secondary Primary Malignancy in Patients With Melanoma

Location of Non-Melanoma Skin Cancers: Same for Both Men and Women?

NCCN Annual Conference: Managing Basal Cell and Squamous Cell Skin Cancers by Risk Status

AACR 2024: Rural Residency and Melanoma Mortality

NCCN Annual Conference: Update on Managing Cutaneous Melanoma

Relationship Between Somatic Mutations and Risk of Skin Cancer Under Investigation

Trends in Melanoma Surveillance and Their Clinical Implications

Some Antihypertensive Drugs May Increase Susceptibility to Skin Cancer, Study Finds

AACR 2024: Biomarker Offers Clues to Melanoma Resistance to Immune Checkpoint Blockade

AACR 2024: Novel Biomarker and Potential Therapeutic Target Identified in Cutaneous SCC

Detecting and Preventing Skin Cancer for Individuals With Intellectual Disabilities

Anti–PD-L1 Refractory Melanoma: Combining Tyrosine Kinase and PD-1 Inhibitors

Noncoding Genes and Therapeutic Research in Basal Cell Carcinoma

SSO 2024: Do Surgical Characteristics Impact TIL Therapy Outcomes in Melanoma?

AAD 2024: Frankincense Application May Impact Melanoma Diagnosis

Targeting Cutaneous and Rare Melanoma Subtypes With Anti-TYRP1 CAR T-Cell Therapy

AAD 2024: Case Study Opens Debate About Surveillance After Merkel Cell Carcinoma

SSO 2024: Understanding Recurrence of Cutaneous Melanoma During and After Adjuvant Immunotherapy

AAD 2024: Keynote Speaker William Shatner Shares His Journey With Stage IV Melanoma

AAD 2024: ‘Sustained’ Activity Reported With Sonidegib in Locally Advanced Basal Cell Carcinoma

Novel T-Cell Therapy After PD-1 Blockade Under Study in Merkel Cell Carcinoma

AAD 2024: Melanoma Subtype–Specific Outcomes in Black vs White Patients

AAD 2024: Factors Associated With Skin Graft Receipt and Hospital Charges in Basal Cell Carcinoma

Combined-Modality Approach to Treatment of Basal Cell Carcinoma of the Head and Neck